Pre-market hot trades in US stocks: Aureus Greenway pre-market down 8.16%; ADC Therapeutics SA pre-market down 7.59%

Popular Pre-Market Trades in U.S. Stocks Aureus Greenway, down 8.16% in pre-market trading, has had no significant news recently. The trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. ADC Therapeutics SA is down 7.59% in pre-market trading. Based on recent key news: On December 3rd, ADC Therapeutics SA announced the latest data from the LOTIS-7 clinical trial, showing that ZYNLONTA combined with a bispecific antibody has the potential to be the best treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma. This news led to a decline in stock price as the market's reaction to the trial results was not as positive as expected. On December 4th, updated LOTIS-7 data indicated that ZYNLONTA plus glofitamab achieved an 89.8% overall response rate (ORR) and a 77.6% complete response (CR) rate in second-line DLBCL, demonstrating durable responses and manageable safety. However, concerns about safety and efficacy remain in the market, leading to continued pressure on the stock price. On December 3rd, ADC Therapeutics SA's major milestones for 2025 include advancing AL102 to phase three data and pushing forward the ADC pipeline development. Despite showing early activity, market doubts about its ability to surpass competitors have impacted stock performance. The biotechnology industry has seen increased volatility recently, warranting attention. Top Gainers in Pre-Market Trading in U.S. Stocks Polyrizon, up 126.49% in pre-market trading, has had no significant news recently. The trading is active with clear capital flows, and considering the sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Kala Pharmaceuticals is up 65.41% in pre-market trading. Based on recent key news: On December 1st, Kala Pharmaceuticals announced a $6 million securities purchase agreement with investor David Lazar and appointed Lazar as CEO and Chairman of the Board. This move has boosted market confidence in the company's future development, driving the stock price up. On December 4th, Kala Bio Inc. submitted a preliminary beneficial ownership statement to the U.S. Securities and Exchange Commission, confirming Oxford Finance LLC as the beneficial owner. This move may affect the company's shareholder structure, further attracting market attention. On December 4th, Kala Pharmaceuticals' stock price has fallen 88% year-to-date, but recent leadership changes and strategic adjustments may bring new development opportunities for the company, prompting investors to reassess its market value. The biopharmaceutical industry has seen significant volatility recently, necessitating attention to policy changes. Picard Medical is up 23.26% in pre-market trading. Based on recent key news: On December 4th, Picard Medical presented in vitro data of the Emperor artificial heart at an international conference. The product does not require external pneumatic drive, demonstrating self-regulation and afterload independence, and confirming the surgical feasibility and performance of the first in-body implantation. These results support future chronic animal studies and clinical translation, driving the stock price up. On December 3rd, Picard Medical submitted an 8-K filing to the U.S. Securities and Exchange Commission, detailing the technical progress and market potential of the Emperor artificial heart, enhancing investor confidence and further driving the stock price up. The medical device industry has performed strongly recently, with significant capital inflows